🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "significant breakthrough" in the battle against increasingly resistant strains of the pathogen, according to scientists.

A Worldwide Challenge

Gonorrhoea infections are on the rise around the world, with estimates suggesting more than 82 million instances annually. Particularly high rates are seen in Africa and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have reached a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune development in the reality of rising global incidence, increasing antimicrobial resistance and the very limited therapeutic options presently on offer.”

Health officials are deeply concerned about the rise in antibiotic-resistant strains. The global health body has listed it as a "high-priority threat". A tracking program revealed that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Secure Approval

One new antibiotic, also known as Nuzolvence, was approved by the US Food and Drug Administration in recent days for combating gonorrhoea. This STI can lead to major issues, including infertility. Researchers believe that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, also received approval in close succession. This drug, which is employed against urinary tract infections, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment was the result of a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to develop it.

“This milestone signifies a huge turning point in the treatment of highly resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Data and Worldwide Availability

Based on findings published in a major medical journal, the new drug successfully treated over nine in ten of uncomplicated infections. This puts it on an comparable level with the typical regimen, which involves an injection and a pill. The study enrolled hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the authority to register and commercialise the drug in many developing nations.

Medical professionals on the front lines have voiced optimism. Having a single-dose, oral treatment of this kind is described as a "revolutionary step" for managing the epidemic. This is considered essential to lessen the impact of the illness for people and to halt the transmission of untreatable gonorrhoea globally.